

Wolfgang D Schmitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6161747/publications.pdf>

Version: 2024-02-01

46
papers

5,581
citations

201385

27
h-index

264894

42
g-index

48
all docs

48
docs citations

48
times ranked

9208
citing authors

#	ARTICLE	IF	CITATIONS
1	Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 581-581.	0.8	3
2	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	3.2	27
3	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 2021, 13, 1076.	1.7	5
4	Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers, 2021, 13, 1512.	1.7	14
5	Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy. Annals of Oncology, 2021, 32, 500-511.	0.6	9
6	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	1.3	41
7	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	5.1	248
8	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	1.8	2
9	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. European Journal of Cancer, 2019, 114, 76-88.	1.3	37
10	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69 – GeparSepto. Journal of Clinical Oncology, 2019, 37, 2226-2234.	0.8	95
11	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	3.2	32
12	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Human Pathology, 2019, 85, 299-308.	1.1	24
13	MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. Proteomics - Clinical Applications, 2019, 13, e1700181.	0.8	45
14	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23
15	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	5.1	1,327
16	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, 104-104.	0.8	43
17	Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).. Journal of Clinical Oncology, 2018, 36, 527-527.	0.8	0
18	Abstract S1-09: Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients. , 2017, , .		12

#	ARTICLE	IF	CITATIONS
19	A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 3062-3062.	0.8	11
20	Ki67 as a prognostic factor in low grade serous ovarian cancer (LGSOC): A retrospective analysis of the Tumor Bank Ovarian Cancer (TOC).. Journal of Clinical Oncology, 2017, 35, 5562-5562.	0.8	1
21	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget, 2017, 8, 102912-102922.	0.8	57
22	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5747-5754.	3.2	158
23	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoâ€”GBC 69): a randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 345-356.	5.1	316
24	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Research, 2016, 76, 796-804.	0.4	74
25	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	0.8	50
26	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€”Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 2015, 33, 983-991.	0.8	863
27	Standardized Ki67 Diagnostics Using Automated Scoringâ€”Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research, 2015, 21, 3651-3657.	3.2	85
28	RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Research and Treatment, 2014, 145, 307-315.	1.1	59
29	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology, 2013, 24, 2786-2793.	0.6	181
30	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4521-4531.	3.2	137
31	Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBC 66)., 2013, , .		16
32	Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. PLoS ONE, 2012, 7, e51862.	1.1	983
33	CDC73/HRPT2 CpG island hypermethylation and mutation of 5â€²-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	1.6	37
34	Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies. Journal of Clinical Oncology, 2010, 28, 3264-3270.	0.8	56
35	Small polydispersed circular DNA contains strains of mobile genetic elements and occurs more frequently in permanent cell lines of malignant tumors than in normal lymphocytes. Oncology Reports, 2009, , .	1.2	11
36	Ribozyme to TGF-Î²1 mRNA abrogates immunosuppressive effects of human colorectal adenocarcinoma HRT-18 cells in vitro and in vivo. International Journal of Oncology, 2009, 35, 901-8.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. <i>International Journal of Oncology</i> , 2009, 36, .	1.4	17
38	Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. <i>Oncogene</i> , 2007, 26, 7584-7589.	2.6	101
39	Transposable elements “ Is there a link between evolution and cancer?. <i>Medical Hypotheses</i> , 2006, 66, 580-591.	0.8	10
40	Ezrin Promotes Ovarian Carcinoma Cell Invasion and Its Retained Expression Predicts Poor Prognosis in Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 121-130.	0.9	59
41	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. <i>Modern Pathology</i> , 2006, 19, 581-587.	2.9	52
42	Influence of Various Cytokines on Adhesion and Migration of the Colorectal Adenocarcinoma Cell Line HRT-18. <i>Oncology</i> , 2005, 68, 33-39.	0.9	6
43	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. <i>American Journal of Pathology</i> , 2005, 167, 879-885.	1.9	27
44	Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 456-464.	1.4	61
45	Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. <i>British Journal of Cancer</i> , 2002, 86, 1310-1315.	2.9	60
46	Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. <i>International Journal of Cancer</i> , 2002, 102, 507-513.	2.3	106